

**The Department of Defense
Breast Cancer Research Program Meeting**

Era of Hope



**The Renaissance Hotel
Washington, DC
October 31 - November 4, 1997**



Registration Information and Preliminary Program

ABOUT THE MEETING

MEETING INTENT

The Era of Hope meeting is designed to share with the scientific community, policy makers and the lay public the work of the Department of Defense (DoD) Breast Cancer Research Program (BCRP). The goal of the BCRP is the ultimate eradication of breast cancer. DoD grant recipients will report on and hear about advancements that have been made since the Program's initiation. The fiscal years 1992-1995 award recipients will attend and present their research. Consumer participation, which has been a hallmark of the peer and programmatic review process from the Program's beginning, will be an integral part of the meeting.

Another goal of the meeting is to provide opportunities for investigators from different fields to share ideas that could lead to novel approaches to difficult research problems. In addition, taxpayers will have an opportunity to learn what has been accomplished with the monies dispensed by the BCRP, and consumers will have an opportunity to learn of the advances in breast cancer prevention, detection, diagnosis, treatment, and quality of life.

UNIFYING THEMES

The meeting will have 3 unifying themes: (1) prevention and detection, (2) genetics and biology, and (3) treatment and quality of life.

The focus for Day 1 of the meeting is on the "frontiers" of prevention and detection. Presentations on this day will center on the current status of breast cancer prevention and detection, and identify major opportunities for progress.

Day 2 sessions will focus on attaining a better understanding of the molecular and cellular pathogenesis of human breast cancer in order to allow for the development of both new and improved strategies to treat and prevent hereditary and nonhereditary breast cancer.

The program for Day 3 centers on presenting the most advanced and up-to-date treatments presently available as well as future treatment possibilities with an emphasis on the best quality of life for the patient, family and significant others.

Day 4 will focus on issues for the future: funding, capacity building—ethnic diversity and outreach, and training new investigators.

FORMAT

A mix of DoD awardees and other renowned scientists, physicians, consumers, and health care providers will address the audience during the Keynote, Plenary and Symposium Sessions. In the afternoon, key leaders in the field will preside over the General Sessions which will specifically highlight the work of DoD recipients. The focus will be on those investigators fostering new directions and addressing neglected issues. During the General Sessions, the Co-chairs will provide a brief overview, introduce platform posters, facilitate attendee interaction, and summarize discussions. In addition, they will have the opportunity to provide "hot" translational material to the "Translational Wrap-up Panel." The "Translational Wrap-up Panel," composed of scientists, physicians and consumers, will provide a general overview of the day's events, highlighting research that can be brought from "bench to bedside" in a timely fashion.

A daily Controversy Session will be held prior to the Translational Wrap-up Panel. The Sessions will feature opposing views on highly controversial topics related to breast cancer. Sunrise sessions, consumer sponsored exhibits, media participation and coverage, and the technical reproduction of some sessions are also planned. All abstracts of FY 1992-1995 award recipients will be displayed as posters; some abstracts will be selected for Platform Presentation.

BCRP LEADERSHIP IN REVIEW

Responding to the National Breast Cancer Coalition's efforts to increase research aimed at overcoming breast cancer, Congress appropriated funds to the Department of Defense in FY92-95 to be directed toward breast cancer research. The U.S. Army's Medical Research and Materiel Command (USAMRMC) was given responsibility for managing the BCRP. A management team of scientists, headed by COL Irene Rich, dedicated themselves to the fight against breast cancer. An Integration Panel (IP) was formed to provide scientific and consumer expertise to fulfill the goals of the Program.

PROGRAM MANAGEMENT TEAM

Russ Zajтчuk, M.D.

Brigadier General, U.S. Army Medical Corps; Commander, USAMRMC; Army Assistant Surgeon General for Research and Development

Irene M. Rich, DNSc.

Colonel, Army Nurse; Director, Research Area VI (RAD VI): Congressional Special Interest Research Programs

Gaylord C. Lindsay III, Ph.D.

Colonel, U.S. Army Medical Services Corps; Deputy Director, RAD VI

Gerald R. Moses, Ph.D.

Deputy Director, BCRP, RAD VI

Steven A. Elg, M.D.

Lieutenant Colonel, U.S. Army Medical Corps; Deputy Director for Oncology, RAD VI

Patricia C. Modrow, Ph.D.

Deputy Director for Science Management, RAD VI

Sharon A. McBride, Ph.D.

Captain, U.S. Army Medical Services Corps, Program Staff Officer, RAD VI

Michael J. McCreery, Ph.D.

Lieutenant Colonel, U.S. Army Medical Corps; Former Deputy Director, BCRP

Hikmat Musallam, Ph.D.

Former Deputy Director, BCRP

Alan Epstein, M.D.

Former Program Manager, BCRP

Yvonne M. Andejski, M.D.

Lieutenant Colonel, U.S. Army Medical Corps; Former Program Manager, BCRP

Gary Weitzman, D.V.M.

Captain, U.S. Air Force, Biomedical Science Corps; Former Program Staff Officer, BCRP

Erich K. Lehnert, Ph.D.

Major, U.S. Army Medical Corps; Former Assoc. Director for Program & Budget, BCRP

Charles B. Templeton, D.V.M., Ph.D.

Major, Former Assoc. Director of Operations & Logistics, BCRP

PAST AND PRESENT INTEGRATION PANEL MEMBERS

The U.S. Army gratefully acknowledges the intellectual strength and vision that the FY92-95 Programmatic Review Panels for breast cancer, mammography/breast imaging, and breast cancer centers provided in crafting a Breast Cancer Research Program that is now underway, reflected in the "Era of Hope" meeting, and for which the Nation as a whole justifiably has great expectations.

Catherine Reznikoff, Ph.D., Chair

Anna D. Barker, Ph.D.,

Chair Emeritus

Helene S. Smith, Ph.D.,

Chair Emeritus

Mina J. Bissell, Ph.D.

Edward Bresnick, Ph.D.

Thomas G. Burish, Ph.D.

Robert Callahan, Ph.D.

Victoria L. Champion, D.N.S.

Deborah E. Collyar

Devra Davis, Ph.D., M.P.H.

Robert Day, M.D., M.P.H., Ph.D.

Marydale DeBor, Esq.

Kay Dickerson, Ph.D.

John R. Durant, M.D.

Dwight Duston, Ph.D.

Laurie Lee Fajardo, M.D.

Harold P. Freeman, M.D.

Emil Frei III, M.D.

Maryellen L. Giger, Ph.D.

Robert M. Gray, Ph.D.

Elizabeth A. Hart, R.N.

William R. Hendee, Ph.D.

Ronald B. Herberman, M.D.

David Hoel, Ph.D.

Jean E. Johnson, Ph.D., F.A.A.N.

Karen Johnson, M.D., Ph.D., M.P.H.

Peter A. Jones, Ph.D.

Patrick Kane, M.B.A.

Ella M. Kelly, Ph.D.

Fredi Kronenberg, Ph.D.

Allen S. Lichter, M.D.

Ngina Lythcott, Dr.P.H.

Ann G. Mahony, Ph.D.

Mary B. Mahowald, Ph.D.

Marsha D. McNeese, M.D.

Maria J. Merino, M.D.

Harold L. Moses, M.D.

Janet Osuch, M.D., F.A.C.S.

Malcolm C. Pike, Ph.D.

Madeline R. Poe, M.S.

E. James Potchen, M.D., J.D., M.B.A.

Jean L. Richardson, Dr.P.H.

Susan M. Sieber, Ph.D.

Dennis Slamon, M.D., Ph.D.

Frances M. Visco, Esq.

Stephen W. Wyatt, D.M.D., M.P.H.

TECHNICAL PROGRAM COMMITTEE

With an eye on the approaching new millennium, the "Era of Hope" Technical Program Committee (TPC) developed a forward looking program that serves as a bridge for facilitating cooperation and communication among scientists, physicians, consumers, and health care providers.

Frances M. Visco, Esq., *TPC Conference Co-chair, IP Member*

President, National Breast Cancer Coalition

E. James Potchen, M.D., J.D., M.B.A., *TPC Conference Co-chair, IP Member*

University Distinguished Professor; Chair, Dept. of Radiology, Michigan State Univ.

Catherine Reznikoff, Ph.D., *IP Chair*

Director, Urologic Oncology Program, Univ. of Wisconsin Comprehensive Cancer Center; Professor of Human Oncology, Univ. of Wisconsin Medical School

Anna D. Barker, Ph.D., *IP Chair Emeritus*

President and CEO, OXIS International, Inc.

Patricia A. Barr, Esq., *Program Representative*

Barr, Sternberg and Moss, P.C.

Elizabeth Hart, R.N., *IP Member*

President and CEO, Hart International

Patricia C. Modrow, Ph.D., *Conference Chair*

Deputy Director for Science Management, RAD VI

Carol A. Evans, *Program/Organizing Representative*

Deputy Manager, Life Sciences Operation, Science Applications International Corp.

Marc E. Lippman, M.D., *Program Representative*

Director, Lombardi Cancer Center, Georgetown University Medical Center

Irene M. Rich, DNSc., *Program Director*

Colonel, Army Nurse; Director, RAD VI

Susan M. Sieber, Ph.D., *IP Member*

Deputy Director, Division of Cancer Epidemiology & Genetics, National Cancer Institute

Dennis J. Slamon, M.D., Ph.D., *IP Member*

Chief, Division of Hematology-Oncology, Director of Clinical & Translational Research at the Jonsson Comprehensive Cancer Center, UCLA School of Medicine

CONFIRMED PRESENTERS TO DATE

(PLUS RESEARCH OF APPROX. 600 AWARD RECIPIENTS)

Karen H. Antman, M.D.

Director, Herbert Irving Comprehensive Cancer Center, Columbia Univ.

Anna D. Barker, Ph.D.

President and CEO, OXIS International, Inc.

Vimla Band, Ph.D.*

Assoc. Professor, Radiation Oncology, New England Medical Center

Patricia A. Barr, Esq.

Barr, Sternberg and Moss, P.C.

Leslie Bernstein, Ph.D.

Professor of Preventive Medicine and Senior Assoc. Dean for Faculty Affairs, Univ. of Southern California, School of Medicine, Dept. of Preventive Medicine

Diane F. Birt, Ph.D.

Eppley Institute for Cancer Research and Life Diseases Professor, Univ. of Nebraska Medical Center

Frank J. Calzone, Ph.D.

Laboratory Head, Molecular Biology, Amgen, Inc.

Graham Casey, Ph.D.*

Assoc. Staff, Department of Cancer Biology, Cleveland Clinic Foundation, Cleveland Clinic Research Institute

Kay Dickersin, Ph.D.

Director of Baltimore Cochrane Center, Associate Professor, Univ. of Maryland School of Medicine

Laura Esserman, M.D., M.B.A.*

Director of UCSF Breast Cancer Center, Dept. of Surgery, Mt. Zion Medical Center, Univ. of California at San Francisco

Laurie L. Fajardo, M.D.

Professor of Radiology and Vice-Chair for Research, Department of Radiology, Univ. of Virginia

Katherine M. Foley, M.D.

Co-Chief, Pain Palliative Care Service, Department of Neurology, Memorial Sloan-Kettering Cancer Center

Judah Folkman, M.D.

Andrus Professor of Pediatric Surgery, Professor of Cell Biology, Harvard Medical School, Children's Hospital

Joe W. Gray, Ph.D.

Director, Cancer Genetics Program, Univ. of California San Francisco Cancer Center

Bettye L. Green, R.N.

Chair for Women in Touch, African American Women in Touch

Geoffrey L. Greene, Ph.D.*

Professor, Ben May Institute for Cancer Research and the Dept. of Biochemistry and Molecular Biology, Univ. of Chicago

I. Craig Henderson, M.D., F.A.C.P.

CEO, Chairman of the Board, SEQUUS Pharmaceuticals, Incorporated

Roy A. Jensen, M.D.

Vanderbilt Univ. Medical Center

Lovell A. Jones, Ph.D.

Professor and Director, Experimental Gynecology and Endocrinology, UT MD Anderson Cancer Center

Randall K. Johnson, Ph.D.

Director, Oncology Research, SmithKline Beecham Assoc.

V. Craig Jordan, Ph.D., D.Sc.*

Professor of Cancer Pharmacology and Director of Breast Cancer Research Program, Northwestern Univ. School of Medicine, Robert H. Lurie Cancer Center

Michael B. Kastan, M.D., Ph.D.

Associate Professor of Oncology, The Johns Hopkins School of Medicine

Benita S. Katzenellenbogen, Ph.D.*

Professor of Physiology and Cell and Structural Biology, Univ. of Illinois

Robert S. Kerbel, Ph.D.

Director, Biological Sciences Program and Division of Cancer Biology Research, Sunnybrook Health Sciences Center, Univ. of Toronto

Mary Claire King, Ph.D.*

American Cancer Society Professor, Depts. of Medicine and Genetics, Univ. of Washington

Ruth L. Kirschstein, M.D.

Deputy Director, National Institutes of Health

Richard D. Klausner, M.D.

Director, National Cancer Institute

Fredi Kronenberg, Ph.D.

Director, The Richard & Hinda Rosenthal Center for Complementary/Alternative Medicine Research in Women's Health, Columbia Univ.

Allen S. Lichter, M.D.

Chairman, Dept. of Radiation Oncology, Univ. of Michigan Medical School

Edison Liu, M.D.*

Director, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health

David Livingston, M.D.*

Chair, Executive Committee for Research, Dana-Farber Cancer Institute

Scott W. Lowe, Ph.D.

Asst. Investigator, Cold Spring Harbor Laboratory

Tak W. Mak, Ph.D.

Sr. Staff Scientist, Amgen Inc., Ontario Cancer Institute

Polly Newcomb, Ph.D.

Assoc. Member, Fred Hutchinson Cancer Research Center

Larry Norton, M.D.*

Chief, Breast Cancer Medical Service, Memorial Sloan-Kettering Cancer Center

Drew M. Pardoll, M.D., Ph.D.

Assoc. Professor, Dept. of Oncology, Medicine, and Molecular Biology and Genetics, The Johns Hopkins Univ. School of Medicine

William P. Peters, M.D., Ph.D.*

President, Director and CEO, Karmanos Cancer Center

Malcolm C. Pike, Ph.D.

Dept. of Preventive Medicine, Univ. of Southern California School of Medicine

E. James Potchen, M.D., J.D., M.B.A.

Univ. Distinguished Professor; Chair, Dept. of Radiology, Michigan State Univ.

Michael Press, M.D., Ph.D.*

Professor of Pathology, Univ. of Southern California

Irene M. Rich, DNSc.

Colonel, Army Nurse; Director, RAD VI

Eleanor G. Rogan, Ph.D.*

Professor, Univ. of Nebraska Medical Center, Eppley Institute for Cancer Research

Julia H. Rowland, Ph.D.

Psycho-Oncology Program, Dept. of Psychiatry, Georgetown Univ. Medical Center

Norman L. Sadowsky, M.D.

Director, Faulkner Sagoff Center

Laura K. Shawver, Ph.D.

Vice President, Preclinical and Pharmaceutical Development, SUGEN, Inc.

Jerry W. Shay, Ph.D.*

Professor of Cell Biology, Univ. of Texas, Southwestern Medical Center at Dallas, Dept. of Cell Biology & Neuroscience

Mark H. Skolnick, Ph.D.

Exec. Vice President of Research, Myriad Genetics, Inc.

Dennis J. Slamon, M.D., Ph.D.*

Chief, Division of Hematology-Oncology, Director of Clinical & Translational Research at the Jonsson Comprehensive Cancer Center, UCLA School of Medicine

Patricia S. Steeg, Ph.D.

Chief of Women's Cancer Section, Laboratory Pathology, National Cancer Institute, National Institutes of Health

Louise C. Strong, M.D.

Professor of Pediatrics/Genetics, UT MD Anderson Cancer Center

Shelia E. Taube, Ph.D.

Assoc. Director, Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health

Ann Thor, M.D.

Professor, Northwestern Medical School, and Dept. of Pathology and Surgery, Evanston Hospital

Thea D. Tlsty, Ph.D.

Assoc. Professor of Pathology, Univ. of California at San Francisco

Harold Varmus, M.D.

Director, National Institutes of Health

Frances M. Visco, Esq.

President, National Breast Cancer Coalition

Daniel D. Von Hoff, M.D., F.A.C.P.*

Director, Institute for Drug Development, Cancer Therapy and Research Center

Antronette Yancey, M.D., M.P.H.

Director, Dept. of Public Health, City of Richmond, VA

* Designates past and present award recipients.

PRELIMINARY MEETING AGENDA

Friday, October 31, 1997

4:00 PM - 9:00 PM **Registration Center Open**
7:30 PM - 9:00 PM **Welcome Reception**

Saturday, November 1, 1997

FRONTIERS IN PREVENTION AND DETECTION

6:45 AM - 7:00 PM **Registration Center Open**
6:45 AM - 8:00 AM **Continental Breakfast Available**
7:45 AM **Welcome and Vision**
8:15 AM **Keynote Address** - Eradication of Breast Cancer: Thoughts from the Frontier
8:45 AM **Plenary Presentation** - Breast Cancer Prevention and Detection: What's Real and What's Next?
9:35 AM **Symposium**

- Molecular Genetics/Biology of Breast Cancer: Tools for Early Detection and Prevention
- Early Detection: Research Frontiers in Imaging
- New Directions in Epidemiology
- Gene Therapy: Potential Role in Breast Cancer Prevention/Treatment
- Role of Lifestyles in Prevention of Breast Cancer
- Bioethics and Genetics-Based Prevention Strategies for Breast Cancer
- Detection and Prevention of Breast Cancer as Viewed by Breast Cancer Consumers

2:00 PM - 3:00 PM **General Session I: Leaders in the Field with Selected Abstracts for Platform Presentation - Concurrent Sessions**
Participants are free to attend one or all of the following sessions:

- Epidemiology
- Access to Care: The Underserved
- Imaging I
- Carcinogenesis

3:00 PM - 4:00 PM **General Session II: Leaders in the Field with Selected Abstracts for Platform Presentation - Concurrent Sessions**
Participants are free to attend one or all of the following sessions:

- Cancer Biomarkers
- Environmental Factors
- Imaging II
- Prevention

4:00 PM **Controversy Session** - Controversies and Policies in Breast Cancer Screening
5:00 PM **Translational Wrap-Up Session**
5:40 PM **Posters/Consumer Exhibits**

Sunday, November 2, 1997

GENETICS AND BIOLOGY OF BREAST CANCER

7:00 AM - 7:00 PM **Registration Center Open**
7:00 AM - 8:00 AM **Continental Breakfast Available**
7:30 AM **Sunrise Sessions - Concurrent Sessions**

- Registries and Resources
- Biological Markers in Tumors
- Consumer Issues in Clinical Trials
- Molecular Cytogenetics

8:45 AM **Pathology Session** - Importance of Pathological Diagnosis
9:05 AM **Plenary Presentation** - Molecular and Cellular Pathogenesis of Human Breast Cancer
9:35 AM **Symposium**

- Oncogenes and Tumor Suppressor Genes
- Growth Factors/Signaling: Role of Growth Factor Alterations
- Hormones/Signaling: Role of Hormone Responsiveness and Resistance
- The Metastatic Cascade

1:00 PM - 2:30 PM **General Session III - Leaders in the Field with Selected Abstracts for Platform Presentation - Concurrent Sessions**
Participants are free to attend one or all of the following sessions:

- Normal Mammary Epithelial Cell Growth and Differentiation
- Oncogenes
- Angiogenesis
- Cell Cycle/Growth

Sunday, November 2, 1997 (cont.)

2:30 PM - 4:00 PM **General Session IV - Leaders in the Field with Selected Abstracts for Platform Presentation - Concurrent Sessions**
Participants are free to attend one or all of the following sessions:

- Genetic Pathogenesis
- Tumor Suppressor Genes
- Metastases
- Hormones

4:00 PM **Emerging Issues in BRCA1**
5:00 PM **Translational Wrap-Up Session**
5:40 PM **Posters/Consumer Exhibits**

Monday, November 3, 1997

TREATMENT AND QUALITY OF LIFE

7:00 AM - 7:00 PM **Registration Center Open**
7:00 AM - 8:00 AM **Continental Breakfast Available**
7:30 AM **Sunrise Sessions - Concurrent Sessions**

- Normal Cellular Responses to DNA Damaging Agents
- Quality of Life
- Novel Therapeutics
- Design and Implementation of Clinical Trials

8:40 AM **Pathology Session** - Future Genetic Biomarkers
9:00 AM **Plenary Presentation** - Challenges in Treating Breast Cancer
9:50 AM **Symposium**

- Current and New Surgical/Chemotherapy Regimes
- Antiestrogen Therapies: Mechanisms Underlying Hormone Responsiveness and Resistance
- Radiation/Combination/Local Therapy: Role of Radiotherapy in Treating Breast Cancer
- Molecular Therapeutics: Targeting Altered Genes or Gene Products
- Quality of Life

1:30 PM - 2:20 PM **General Session V - Leaders in the Field with Selected Abstracts for Platform Presentation - Concurrent Sessions**
Participants are free to attend one or all of the following sessions:

- Novel Therapeutics
- Local Therapy
- Drug Resistance
- Psychosocial

2:20 PM - 3:10 PM **General Session VI - Leaders in the Field with Selected Abstracts for Platform Presentation - Concurrent Sessions**
Participants are free to attend one or all of the following sessions:

- Models/Tumor Immunology/Gene Therapy
- Hormone Therapy
- Nutritional Therapy

3:15 PM - 4:15 PM **Controversy Session** - Stem Cell Transplantation
4:15 PM - 5:15 PM **Controversy Session** - Tamoxifen/Hormones
5:15 PM - 5:45 PM **Translational Wrap-Up Session**
6:00 PM - 7:00 PM **Posters/Consumer Exhibits**
7:30 PM **ERA OF HOPE BANQUET**

Tuesday, November 4, 1997

ISSUES FOR THE FUTURE

7:00 AM - 9:30 AM **Registration Center Open**
7:00 AM - 8:00 AM **Continental Breakfast Available**
8:00 AM **Training Grants: New Investigators**
10:00 AM **Capacity Building: Ethnic Diversity and Outreach**
10:45 AM **DoD Breast Cancer Research Program and the National Academy of Sciences' Institute of Medicine**
11:15 AM **Funding in Breast Cancer**
12:30 PM **Adjourn**

LOGISTICAL INFORMATION

MEETING LOCATION

Renaissance, Washington D.C. Hotel
999 9th Street, N.W., Washington, D.C. 20001-9000
Tel: (202) 898-9000 FAX: (202) 789-4213

REGISTRATION

All participants must register for the meeting using the enclosed "Advance Registration Form." Please return the form along with your registration fees by September 15, 1997 to obtain reduced registration rates and to ensure the receipt of your badge and all meeting publications. Registrations received between September 15 and October 3 will be accepted at the late fee amount. If registration is received after October 3, it will be returned to the sender and that person will have to register on-site at the on-site rate. See "On-site Registration Hours" for further details. Registration confirmation will be faxed to all participants. Registration fees are:

Received by September 15	\$200
Received between September 15 & October 3	\$225
On-site Registration (anything after October 3)	\$250

The Registration Fee provides (1) admittance to all scientific and poster sessions, (2) continental breakfast on Saturday through Tuesday, (3) AM and PM refreshments concurrent with the technical program sessions, and (4) one copy of the Conference Proceedings and Program Booklet plus conference materials. Advance registration is encouraged to ensure on-site receipt of Proceedings and Program Booklet. The sole intent of the registration fee is to promote, enhance and facilitate technical discussions and long-term professional relationships/collaborations in breast cancer research.

HOTEL ACCOMMODATIONS

Rooms have been reserved at several hotels in the Washington, DC area. To make reservations at the participating hotels, attendees must complete the enclosed "Housing Reservation Form" and return it to SAIC Travel-Conference Services no later than September 15, 1997.

The hotels will not accept individual call-in reservations. Participants will first be placed at the conference site, the Renaissance Hotel (preference must be given to speakers, presenters, and program participants). Once the room block at the Renaissance is filled, participants will be placed at one of the conference overflow hotels. Please refer to the "Host and Overflow Hotel List and Location Map" for hotels, room rates, and locations. Reservations received after September 15, 1997 will be accepted on a space and rate availability basis only. *Availability is not guaranteed, so reserve early.*

WELCOME RECEPTION

A Welcome Registration Reception is planned for Friday, October 31, from 7:30 - 9:00 PM in the Renaissance Ballroom.

ON-SITE REGISTRATION HOURS

On-site registration will be in the Grand Ballroom Foyer of the Renaissance Hotel during the following dates and times:

Friday, October 31	4:00 PM - 9:00 PM
Saturday, November 1	6:45 AM - 7:00 PM
Sunday, November 2	7:00 AM - 7:00 PM
Monday, November 3	7:00 AM - 7:00 PM

TRANSPORTATION

Airports

The Renaissance is located 10 minutes from Washington National Airport and approximately 45 minutes from both Dulles and Baltimore-Washington International (BWI). Amtrak's Union Station is less than 3 minutes away.

Ground Transportation

The Chinatown Metro Rail Stop (Yellow & Green Line) is located 2 blocks from the hotel. Taxis are available from all 3 airports to the conference site. The average taxi fare from Washington National Airport is \$12. Shuttle service from Washington National (\$8 per person/one-way) and Dulles International Airport (\$12 per person/one-way) is available through The Washington Flyer. Please contact the shuttle service directly at (703) 685-1400 for reservations and schedule information. The Super Shuttle, 1-800-258-3826, provides service from BWI to the Renaissance at \$28 per person.

Rental Cars/Hotel Parking

Rental cars are not a necessity in the Washington, DC area due to the ease and accessibility of public transportation. Should you choose to rent a car or if you are a local participant driving to the meeting site, hotel parking is available. Rates are \$15/24-hours and \$9/8-hours.

SAIC Travel

Special discounted airfares are available through SAIC Travel-Conference Services. To make airline or rental car reservations, please complete the "Travel Request Form" and return it to SAIC Travel-Conference Services as soon as possible.

BANQUET

An Era of Hope Banquet is planned for Monday, November 3 at the Renaissance Hotel. Tickets are \$35 per person for a three-course meal; a cash bar will be available throughout the evening. Additional details will be forwarded to you as soon as they become available.

CONTINUING EDUCATION ACCREDITATION

Conference organizers are investigating offering Continuing Medical Education (CME) and Continuing Education Unit (CEU) credits. Please indicate on the enclosed Advance Registration Form if you would be interested in CME or CEU credits. Additional details and procedures will be available during registration.

QUESTIONS?

General Issues (Housing, Registration, etc.)

Carla L. Post, SAIC
5340 Spectrum Drive, Suite N
Frederick, Maryland 21703
Phone: 301-228-3128 Fax: 301-698-6188

Abstract and Poster Presentation Questions:

Sandra J. Carlson, SAIC
5340 Spectrum Drive, Suite N
Frederick, Maryland 21703
Phone: 301-228-3127 Fax: 301-698-6188

Alternate main SAIC phone number: (301) 698-5991

Internet: Updated meeting information will be available on the Internet by late June.
The address is: <http://mrmc-rad6.army.mil>

SPEAKER INFORMATION AND POSTER GUIDELINES

SPEAKER INFORMATION/PRESENTATION FORMAT

Opening, Keynote, Plenary, Symposium, Pathology and Controversy Sessions will be presented in double projection; speakers are requested to bring two sets of 35 mm slides for this purpose.

Speakers should plan to arrive at the meeting room approximately 15 minutes before the session begins, notify the session chair of their arrival, and give their slides to the projectionist.

Slide Preparation

All slides should be duplicates, not originals, in case of loss or damage. Slides should be thumb-spotted by placing a mark in the upper right-hand corner of the slide when it is loaded properly in the slide tray, and numbered in the proper sequence. Use standard horizontal format. Vertical and super slides should be avoided. Extra slide carousels will be available. It is approximately 120 feet from the projection screens to the last row of the plenary conference room so please plan your font sizes accordingly.

POSTER SESSION SETUP

Presenters must have their posters assembled and ready for display in Congressional Hall by 4:00 PM, November 1. Poster boards will be available for setup between 8:00 PM and 10:00 PM on October 31 and 7:00 AM and 4:00 PM on November 1. Poster assignment numbers will be displayed in front of the exhibit hall as well as listed in the Program Booklet. Posters are to remain on display until 7:30 PM, November 3. All materials must be removed by 12:00 noon on November 4. Please refer to the "Poster Format Guidelines."

INSTRUCTIONS FOR "ERA OF HOPE" MEETING

POSTER PRESENTATIONS

Extended abstracts scheduled for presentation in poster sessions will be grouped by topic, numbered, and listed in the final program.

Posters should be readable by reviewers 5 feet away. The message should be clear and understandable without oral explanation. Illustrations, labels, etc. must be attached to the poster board with thumbtacks, which will be available in the poster area. Do not write on the poster boards.


Please leave space in the upper left-hand corner of the poster board for a poster number. This number will be given to you during setup. A copy of your extended abstract should be posted to the right of the poster board number. A label indicating the extended abstract title, author, and the affiliation should be placed at the top of the poster board, to the right of the abstract. A label listing the funding

source(s) and grant identification (DAMD number) must be displayed in the lower right corner of the poster board.

POSTER FORMAT GUIDELINES

The poster board surface area is 3'8" high and 7'6" wide (approximately 110cm x 230cm). The following guidelines have been prepared to help improve the effectiveness of poster communication.

1. **Initial Sketch:** Plan your poster early. Focus your attention on a few points. Try various styles of data presentation to achieve clarity and simplicity. Does the use of color help? What needs to be expressed in words? Suggest headlines and text topics.
2. **Rough Layout:** Enlarge your best initial sketch, keeping the dimensions in proportion to the final poster (see diagram). Ideally, the rough layout should be full size. A blackboard is a convenient place to work. Print the title and headlines. Indicate text by horizontal lines. Draw rough graphs and tables. This will give you a good idea of proportions and balance. If you are working with an artist, show him or her the poster layout. Ask associates for comments. This is still an experimental stage.
3. **Final Layout:** The artwork is complete. The text and tables are typed but not necessarily enlarged to full size. Now ask, is the message clear? Do the important points stand out? Is there a balance between words and illustrations? Is there spatial balance? Is the pathway through the poster clear?
4. **Balance:** The figures and tables should cover slightly more than 50% of the poster area. If you have only a few illustrations, make them large. Do not omit the text, but keep it brief. Be sure every illustration has a brief caption. The poster should be understandable without oral explanation.
5. **Typography:** Avoid abbreviations, acronyms and jargon. Use a consistent type of style throughout. Use large type, for example, ORATOR. An 8 1/2" x 11" sheet of paper photostatically enlarged 50% makes the text readable from 5 feet.
6. **Eye Movement:** The movement (pathway) of the eye over the poster should be natural—down the columns or along the rows. Size attracts attention. Arrows, pointing hands, numbers, and letters can help clarify the sequence.
7. **Simplicity:** The temptation to overload the poster should be resisted. More material may mean less communication.




Map#	Hotel Name	Address	Single	Double
1	Host Hotel: Renaissance, Washington, DC Hotel ^M Rooms in the Main Hotel Bethesda Marriott (shuttle to metro)	999 9th Street, NW 6161 Pooks Hill Road, Bethesda, Maryland 14th & K Streets, NW 300 Army Navy Drive, Arlington, Virginia	\$124 \$144 \$123.20	\$144 \$164 \$123.20
2	Crowne Plaza Hotel ^M Doubletree Pentagon City ^M	1500 New Hampshire Ave., NW 560 C Street, SW	\$124 \$124	\$134.11 \$124
3	Dupont Plaza Hotel ^M Holiday Inn Capitol ^M	415 New Jersey Avenue 15th & Pennsylvania, NW	\$124 \$124.67	\$134 \$124.67
4	Hotel Washington ^M Madison Hotel ^M	15th & M Street, NW 775 12th Street, NW	\$154 \$135.97	\$154 \$135.97
5	Marriott at Metro Center ^M Renaissance Mayflower Hotel	1127 Connecticut Ave, NW 1400 M Street, NW	\$124 \$124	\$124 \$142.92
6	The Westin (formerly the Vista) ^M Wyndham Bristol Hotel ^M	2430 Pennsylvania Ave., NW Courthouse Plaza, Arlington, Virginia	\$123.54 \$112.97	\$146.14 \$112.97
7	Quality Hotel ^M			

HOTEL RATES ARE INCLUSIVE OF THE PREVAILING STATE OR DISTRICT SALES TAX AND OCCUPANCY FEE. Government per diem for lodging in Washington, DC is \$124.00. If per diem should change before the meeting occurs, some of the above rates may also change. ^MIndicates the hotel is Metro accessible.

Points of Interest

- A White House
- B Union Station
- C U.S. Capitol
- D Smithsonian Institute
- E Jefferson Memorial
- F Washington Monument
- G Lincoln Memorial
- H Department of State
- I Arlington Cemetery
- J Supreme Court
- K Library of Congress
- L Nat'l Postal Museum





ERA OF HOPE

DATES TO REMEMBER

As soon as possible...

Return Housing Form

Make Travel Reservations

Monday, September 15, 1997

Advance Registration Deadline

Housing Reservation Forms Due

Friday, October 3, 1997

Last Day to Mail in Advance Registration Form